Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07054073 · ClinicalTrials.gov registry record
HCMR Re-Imaging Study
A clinical trial of Hypertrophic Cardiomyopathy (HCM), sponsored by Christopher Kramer.
- Recruiting
- Registry status
- 314
- Enrollment target
- 8
- Study locations
NCT07054073: Recruiting study of Hypertrophic Cardiomyopathy (HCM), sponsored by Christopher Kramer.
NCT07054073 is a study of Hypertrophic Cardiomyopathy (HCM) that is actively recruiting participants, run by Christopher Kramer. The registered enrollment target is 314 participants. The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07054073, a study of Hypertrophic Cardiomyopathy (HCM), is actively recruiting participants, sponsored by Christopher Kramer.
- RECRUITING
- Registry status
- 314 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system. This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.
Primary Outcome
To assess the change in LGE extent from baseline over a minimum of 7 years of follow-up extent in HCM patients who would have been candidates for clinical trials of aficamten.
Conditions Studied
Interventions
- OTHER None - observational study
Study Locations (8)
Massachusetts
- Brigham & Women's Hospital - Boston
- Tufts Medical Center - Medford
Other
- University Hospitals Birmingham NHS Foundation Trust - Birmingham
- London Chest Hospital - London
Illinois
- Northwestern - Evanston
Michigan
- University of Michigan - Ann Arbor
Ohio
- Cleveland Clinic - Cleveland
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2026-03-30 |
| Est. Completion | 2027-07 |
What NCT07054073 shows while recruiting
NCT07054073 is an observational study that tracks outcomes without assigning an intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Hypertrophic Cardiomyopathy (HCM) appearing as the primary indexed condition, and to 1 intervention - of which None - observational study is the first listed.
NCT07054073 lists 8 locations in 6 states (Massachusetts, Other, Illinois).
Frequently Asked Questions
What is clinical trial NCT07054073 about?
NCT07054073 is a clinical study titled "HCMR Re-Imaging Study". This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properl...
What is the current status of trial NCT07054073?
This trial is currently recruiting. The enrollment target is 314 participants. The study started on 2026-03-30. Estimated completion is 2027-07.
What conditions does trial NCT07054073 study?
This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy (HCM).
What interventions are being tested in trial NCT07054073?
The interventions under investigation include: None - observational study (OTHER).
Who is sponsoring clinical trial NCT07054073?
This trial is sponsored by Christopher Kramer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07054073 being conducted?
This trial has 8 study locations across Illinois, Massachusetts, Michigan, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertrophic Cardiomyopathy (HCM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI